CONTEXT: Acquired generalized lipodystrophy (AGL) is marked by severe insulin resistance and hypertriglyceridemia. Rarely, AGL and type 1 diabetes (T1D) coexist. OBJECTIVE: Our objective was to describe the response to leptin therapy in patients with coexisting AGL and T1D and to document the autoimmune diseases associated with AGL. DESIGN AND SETTING: We conducted an open-label prospective study at the Clinical Research Center of the National Institutes of Health. PATIENTS: Participants included 50 patients with generalized or partial lipodystrophy (acquired or congenital); two patients had both AGL and T1D. INTERVENTION: Patients were treated with 12 months of recombinant human leptin administration to achieve high-normal serum concentrations. RESULTS: Two patients had both AGL and T1D. The first was diagnosed with T1D at age 8 yr. Beginning at age 11 yr, he developed generalized lipodystrophy, elevated transaminases, and poor glycemic control [hemoglobin A 1c (HbA 1c) 10.7%] despite markedly increased insulin requirements (3.3-5 U/kg.d). Further evaluation revealed hypoleptinemia and hypertriglyceridemia. At age 15 yr, leptin therapy was initiated, and after 1 yr, his insulin requirements fell to 1 U/kg.d, his glycemic control improved (HbA 1c 8.4%), and both his triglycerides and transaminases normalized. The second patient developed concurrent AGL and T1D at age 6 yr. Despite insulin doses of up to 32 U/kg.d, she developed poor glycemic control (HbA 1c 10.6%), hypertriglyceridemia (2984 mg/dl), elevated transaminases, and nonalcoholic steatohepatitis. At age 13 yr, leptin therapy was started, and after 1 yr, her glycemic control improved (HbA 1c 7.3%) and her insulin requirements decreased (17 U/kg.d). Her triglycerides remained elevated but were improved (441 mg/dl). CONCLUSIONS: Long-term recombinant leptin therapy is effective in treating the insulin resistance of patients with the unusual combination of T1D and AGL.
CONTEXT: Acquired generalized lipodystrophy (AGL) is marked by severe insulin resistance and hypertriglyceridemia. Rarely, AGL and type 1 diabetes (T1D) coexist. OBJECTIVE: Our objective was to describe the response to leptin therapy in patients with coexisting AGL and T1D and to document the autoimmune diseases associated with AGL. DESIGN AND SETTING: We conducted an open-label prospective study at the Clinical Research Center of the National Institutes of Health. PATIENTS: Participants included 50 patients with generalized or partial lipodystrophy (acquired or congenital); two patients had both AGL and T1D. INTERVENTION: Patients were treated with 12 months of recombinant human leptin administration to achieve high-normal serum concentrations. RESULTS: Two patients had both AGL and T1D. The first was diagnosed with T1D at age 8 yr. Beginning at age 11 yr, he developed generalized lipodystrophy, elevated transaminases, and poor glycemic control [hemoglobin A 1c (HbA 1c) 10.7%] despite markedly increased insulin requirements (3.3-5 U/kg.d). Further evaluation revealed hypoleptinemia and hypertriglyceridemia. At age 15 yr, leptin therapy was initiated, and after 1 yr, his insulin requirements fell to 1 U/kg.d, his glycemic control improved (HbA 1c 8.4%), and both his triglycerides and transaminases normalized. The second patient developed concurrent AGL and T1D at age 6 yr. Despite insulin doses of up to 32 U/kg.d, she developed poor glycemic control (HbA 1c 10.6%), hypertriglyceridemia (2984 mg/dl), elevated transaminases, and nonalcoholic steatohepatitis. At age 13 yr, leptin therapy was started, and after 1 yr, her glycemic control improved (HbA 1c 7.3%) and her insulin requirements decreased (17 U/kg.d). Her triglycerides remained elevated but were improved (441 mg/dl). CONCLUSIONS: Long-term recombinant leptin therapy is effective in treating the insulin resistance of patients with the unusual combination of T1D and AGL.
Authors: T Kawai; I Takei; Y Oguma; N Ohashi; M Tokui; S Oguchi; F Katsukawa; H Hirose; A Shimada; K Watanabe; T Saruta Journal: Metabolism Date: 1999-09 Impact factor: 8.694
Authors: Edward D Javor; Marc G Ghany; Elaine K Cochran; Elif Arioglu Oral; Alex M DePaoli; Ahalya Premkumar; David E Kleiner; Phillip Gorden Journal: Hepatology Date: 2005-04 Impact factor: 17.425
Authors: David G Carey; Gary J Cowin; Graham J Galloway; Nigel P Jones; Jackie C Richards; Nandita Biswas; David M Doddrell Journal: Obes Res Date: 2002-10
Authors: Elif Arioglu Oral; Edward D Javor; Li Ding; Gulbu Uzel; Elaine K Cochran; Janice Ryan Young; Alex M DePaoli; Steven M Holland; Phillip Gorden Journal: J Clin Endocrinol Metab Date: 2005-11-29 Impact factor: 5.958
Authors: Edward D Javor; Elaine K Cochran; Carla Musso; Janice Ryan Young; Alex M Depaoli; Phillip Gorden Journal: Diabetes Date: 2005-07 Impact factor: 9.461
Authors: Edward D Javor; Stephanie Ann Moran; Janice Ryan Young; Elaine K Cochran; Alex M DePaoli; Elif Arioglu Oral; Martin A Turman; Piers R Blackett; David B Savage; Stephen O'Rahilly; James E Balow; Phillip Gorden Journal: J Clin Endocrinol Metab Date: 2004-07 Impact factor: 5.958
Authors: May-yun Wang; Lijun Chen; Gregory O Clark; Young Lee; Robert D Stevens; Olga R Ilkayeva; Brett R Wenner; James R Bain; Maureen J Charron; Christopher B Newgard; Roger H Unger Journal: Proc Natl Acad Sci U S A Date: 2010-03-01 Impact factor: 11.205